Search Result

Results for "

PARPs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PARP (241) Adenosine Receptor (1) Adrenergic Receptor (1) Akt (4) AMPK (1) Anaplastic lymphoma kinase (ALK) (1) Androgen Receptor (4) Antibiotic (2) Apoptosis (109) Arenavirus (2) Aryl Hydrocarbon Receptor (1) ATM/ATR (1) Aurora Kinase (1) Autophagy (18) Bacterial (3) Bcl-2 Family (15) c-Met/HGFR (1) c-Myc (1) Caspase (35) CDK (9) Ceramidase (1) CFTR (2) Checkpoint Kinase (Chk) (1) Deubiquitinase (3) Dipeptidyl Peptidase (1) DNA-PK (1) DNA/RNA Synthesis (6) Drug Metabolite (1) Dynamin (1) E3 Ligase Ligand-Linker Conjugates (5) EGFR (2) Endogenous Metabolite (13) Epigenetic Reader Domain (5) ERK (3) Eukaryotic Initiation Factor (eIF) (1) FGFR (3) Fluorescent Dye (2) Glutathione Peroxidase (1) HDAC (8) HIF/HIF Prolyl-Hydroxylase (2) Histone Demethylase (1) Histone Methyltransferase (2) HIV (1) HSP (1) IAP (1) IFNAR (2) IGF-1R (1) IKK (1) Influenza Virus (1) Interleukin Related (2) IRAK (1) Isotope-Labeled Compounds (2) JNK (3) Keap1-Nrf2 (2) Ligands for Target Protein for PROTAC (2) MDM-2/p53 (4) Microtubule/Tubulin (8) Mitochondrial Metabolism (2) Mitophagy (5) Molecular Glues (2) Necroptosis (1) NF-κB (1) Nucleoside Antimetabolite/Analog (7) P-glycoprotein (4) p38 MAPK (7) Parasite (6) PD-1/PD-L1 (2) Phosphatase (3) Phosphodiesterase (PDE) (1) PI3K (3) Poly(ADP-ribose) Glycohydrolase (PARG) (4) PPAR (3) PROTAC Linkers (3) PROTACs (11) Proteasome (1) PSMA (1) Pyroptosis (2) Raf (1) Ras (1) Reactive Oxygen Species (6) Reverse Transcriptase (1) Ribosomal S6 Kinase (RSK) (1) ROS Kinase (1) Salt-inducible Kinase (SIK) (1) SARS-CoV (1) Sirtuin (6) Small Interfering RNA (siRNA) (25) STAT (2) Survivin (2) Target Protein Ligand-Linker Conjugates (1) Topoisomerase (4) VEGFR (3) Wnt (2) β-catenin (1)
By Research Areas:	Cancer (292) Cardiovascular Disease (8) Infection (10) Inflammation/Immunology (20) Metabolic Disease (9) Neurological Disease (27)
Click Chemistry:	PROTAC Synthesis (1) Azide (3) Alkynes (2)
Oligonucleotides:	Nucleosides and their Analogs (4) Nucleoside Phosphoramidites (2) Pre-designed siRNA Sets (25) siRNAs (25)

371

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: PARP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-105692

DR2313	PARP	Neurological Disease
DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC₅₀s of 0.20 μM and 0.24 μM for *PARP-1* and *PARP-2*, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo .

HY-10162S

Olaparib-d5 AZD2281-d₅; KU0059436-d₅	PARP Autophagy Mitophagy	Cancer
Olaparib-d₅ is a deuterium labeled Olaparib. Olaparib is a potent and oral PARP inhibitor[1].

HY-125218

PARP11 inhibitor ITK7 ITK7	PARP	Cancer
PARP11 inhibitor ITK7 (ITK7) is a potent and selective *PARP11* inhibitor. PARP11 inhibitor ITK7 can potently inhibit PARP11 with an IC₅₀ value of 14 nM. PARP11 inhibitor ITK7 can be used for the research of cellular localization .

HY-159612

PARP1-IN-28	PARP	Cancer
PARP1-IN-28 (compound 1) is a *PARP1* inhibitor. PARP1-IN-28 can be used in the study of cancer .

HY-D1107

NCT-TFP	PARP	Others
NCT-TFP is PARP probe used to identifying Poly(ADP-ribose) polymerases (PARP) inhibitors (extracted from patent US20190331688A1) .

HY-10885

A-620223 succinate ABT-472	PARP	Cancer
A-620223 succinate (ABT-472) is an orally available poly(ADP-ribose) polymerase (PARP) inhibitor. A-620223 succinate (ABT-472) exhibits very good potency against the PARP-1 enzyme with a K_i value of 8 nM and an EC₅₀ value of 3 nM in whole cell assay, making it useful in cancer research .

HY-157490

PARP/HDAC-IN-1	PARP HDAC	Cancer
PARP/HDAC-IN-1 (compound B102) is a potent dual inhibitor of *PARP* and HDAC. PARP/HDAC-IN-1 inhibits *PARP1, PARP2* and HDAC1 with IC₅₀s of 19.01, 2.13, 1690 nM, respectively .

HY-W156961

LS-75	PARP	Neurological Disease
LS-75 is a *PARP-1* inhibitor with blood-brain permeability and IC₅₀ value of 18 μM. LS-75 has neuroprotective activity .

HY-157165

*Tubulin/PARP-IN-1*	Microtubule/Tubulin PARP	Cancer
Tubulin/PARP-IN-1 (compound 14) is a dual PARP-tubulin inhibitor with activity against endometrial cancer. *Tubulin/PARP*-IN-1 inhibits PARP and tubulin with IC₅₀s of 74 nM (PARP1), 109 nM (PARP2), and 1.4 μM (Microtubule/Tubulin), respectively. Tubulin/PARP-IN-1 can induce apoptosis and autophagy and cause cell cycle arrest in the G2/M phase .

HY-158799

Poly(ADP-ribose) Polymer/pADPr	Poly(ADP-ribose) Glycohydrolase (PARG)	Others
Poly(ADP-ribose) Polymer/pADPr is a complex polymer of repeating ADP-ribose units, which is synthesized using poly(ADP-ribose) polymerase (PARP) in the presence of NAD ⁺, cleaved from PARP, and subsequently purified .

HY-132167

Saruparib 5+ Cited Publications AZD5305	PARP	Cancer
Saruparib (AZD5305) is a potent, orally active and selective *PARP* inhibitor and trapper with IC₅₀ values of 3 nM and 1400 nM for PARP1 and PARP2, respectively. Saruparib has anti-proliferative activity and inhibits growth in cells with deficiencies in DNA repair .

HY-141486A

*PROTAC PARP/EGFR ligand 1*	PARP EGFR Ligands for Target Protein for PROTAC	Others
PROTAC PARP/EGFR ligand 1 is an active compound that can be used for the synthesis of dual PARP EGFR degraders by proteolytic targeting chimera (PROTAC) technology .

HY-121719

TIQ-A	PARP	Cardiovascular Disease Cancer
TIQ-A is a potent TNKS (poly-ART, PARP) inhibitor, with an IC₅₀ of 24 nM for TNKS2. TIQ-A is a potential anti-ischemic agent .

HY-131009

Fluorescein-NAD+	PARP	Others
Fluorescein-NAD+ is an alternative to radiolabeled NAD and a substrate for ADP-ribosylation. Fluorescein-NAD+ can be used in PARP assays by fluorescence microscopy. Extinction Coefficient: 262 nm.

HY-160409

TopBP1-IN-1	Others Topoisomerase	Cancer
TopBP1-IN-1 is a TopBP1 inhibitor. TopBP1-IN-1 has a synergistic effect with *PARP* inhibitors. TopBP1-IN-1 has antitumor activity .

HY-134354

pNP-ADPr ADP-ribose-pNP	Poly(ADP-ribose) Glycohydrolase (PARG)	Others
pNP-ADPr is a colorimetric substrate that used for the first continuous Poly(ADP-ribose) glycohydrolase (PARG) and ADP-ribosyl hydrolase 3 (ARH3) activity assays. pNP-ADPr can be used for the research of poly(ADP-ribose)polymerase (PARP) enzymes .

HY-N7569

Demethoxyfumitremorgin C	Apoptosis Caspase PPAR	Cancer
Demethoxyfumitremorgin C is a secondary metabolite of the marine fungus, Aspergillus fumigatus. Demethoxyfumitremorgin C induces prostate cancer cell apoptosis. Demethoxyfumitremorgin C activates caspase-3, -8, and -9, leading to **PARP/ cleavage .**

HY-120115

PARPi-FL Olaparib-bodipy FL	PARP Fluorescent Dye	Cancer
PARPi-FL is a small molecule and fluorescent inhibitor of *PARP1*. PARPi-FL is a highly selective probe and can be used as an imaging agent to detect glioblastomas in vivo. (Excitation/Emission max 507/525 nm) .

HY-150696

Antitumor agent-72	Apoptosis Caspase PARP	Cancer
Antitumor agent-72 (compound 6w) is a potent anticancer agent. Antitumor agent-72 has anticancer activity and induces apoptosis through activation of caspase-3 and cleavage of PARP. Antitumor agent-72 can be used for cancer research .

HY-155993

YCH1899	PARP	Cancer
YCH1899 is an orally active *PARP* inhibitor, with an IC₅₀< 0.001 nM for PARP1/2. YCH1899 exhibits distinct antiproliferation activity against Olaparib (HY-10162)-resistant and Talazoparib (HY-16106)-resistant Capan-1 cells (Capan-1/OP and Capan-1/TP cells) , with IC₅₀ values of 0.89 and 1.13 nM, respectively. YCH1899 has acceptable pharmacokinetic properties in rats .

HY-W424851

DPQ hydrochloride 6,7-Dimethoxy-2-(1-piperazinyl)-4-quinazolinamine hydrochloride	PARP	Infection Inflammation/Immunology
DPQ hydrochloride (6, 7-dimethoxy-2 -(1-piperazinyl)-4-quinazolinamine hydrochloride) is a *PARP1* inhibitor, with IC₅₀ value of 40 nM. DPQ hydrochloride has anti-inflammatory and antiviral activity. DPQ hydrochloride is used to study acute lung injury .

HY-13540

E7016 GPI 21016	PARP	Cancer
E7016 (GPI 21016) is an orally available *PARP* inhibitor. E7016 can enhance tumor cell radiosensitivity in vitro and in vivo through the inhibition of DNA repair. E7016 acts as a potential anticancer agent .

HY-144874

AZ3391	PARP	Neurological Disease Cancer
AZ3391 is a potent inhibitor of *PARP. AZ3391 is a quinoxaline derivative. PARP* family of enzymes play an important role in a number of cellular processes, such as replication, recombination, chromatin remodeling, and DNA damage repair. AZ3391 has the potential for the research of diseases and conditions occurring in tissues in the central nervous system, such as the brain and spinal cord (extracted from patent WO2021260092A1, compound 23) .

HY-157137

PARP1-IN-17	PARP Caspase Apoptosis	Cancer
PARP1-IN-17 is a *PARP-1* inhibitor (IC₅₀ = 19.24 nM for *PARP-1* and = 32.58 nM for PARP-2) and induce apoptosis. PARP1-IN-17 shows excellent anti-proliferative activity .

HY-153590

PARP-1-IN-4	PARP	Cancer
PARP-1-IN-4 is a *PARP-1* inhibitor. PARP-1-IN-4 has inhibitory activity against PARP-1 with IC₅₀ value of 302 μM. PARP-1-IN-4 can be used for the research of lung adenocarcinoma .

HY-149800

PARP-1-IN-3	PARP Apoptosis Caspase	Cancer
PARP-1-IN-3, a benzamide derivative, is a potent *PARP-1* inhibitor with IC₅₀ values of 0.25 nM and 2.34 nM for PARP-1 and PARP-2, respectively. PARP-1-IN-3 induces apoptosis and arrest cell cycle at G2/M phase. PARP-1-IN-3 can be used in research of cancer .

HY-105253

PARP-2/1-IN-2	PARP	Neurological Disease
PARP-2/1-IN-2 (Compound 4a), the enantiomer of Veliparib (HY-10129), is a potent *PARP* inhibitor with K_is of 2 and 5 nM against *PARP-2* and *PARP-1, respectively. PARP-2/1-IN-2 has an EC₅₀ of 3 nM in a cell based assay of PARP* activity .

HY-P2569

Malformin A1	Apoptosis	Cancer
Malformin A1, a cyclic pentapeptide isolated from Aspergillus niger, possess a range of bioactive properties including antibacterial activity. Malformin A1 shows potent cytotoxic activities on human colorectal cancer cells. Malformin A1 induces apoptosis by activating PARP, caspase 3, -7, and -9 .

HY-148754

PARP10-IN-3	PARP	Cancer
PARP10-IN-3 is a selective mono‐ADP‐ribosyltransferase *PARP10* inhibitor with an IC₅₀ of 480 nM for human PARP10. PARP10-IN-3 reveals potent inhibition on *PARP2* and *PARP15* with IC₅₀s of 1.7 μM for human PARP2 and human PARP15, respectively .

HY-164475

PARP1-IN-29	PARP	Cancer
PARP1-IN-29 is an orally active *PARP-1* inhibitor with an IC₅₀ value of 6.3 nM. PARP1-IN-29, after being labeled with [18F], can be used for positron emission tomography (PET) imaging, specifically targeting *PARP-1* in tumors. PARP1-IN-29 is applicable in the fields of oncology and imaging research, particularly for detecting *PARP-1* activity in cancer .

HY-D1188

PARP7-probe-1	PARP	Cancer
PARP7-probe-1 is a chemiluminescent labeled *PARP7* probe. PARP7-probe-1 is a biotinylated probe binding to the PARP7 active site. PARP7-probe-1 can be used for the research of PARP7 function .

HY-148753

PARP10-IN-2	PARP	Cancer
PARP10-IN-2 is a potent mono‐ADP‐ribosyltransferase *PARP10* inhibitor with an IC₅₀ of 3.64 μM for human PARP10. PARP10-IN-2 reveals potent inhibition on *PARP2* and *PARP15* with IC₅₀s of 27 μM and 11 μM for human PARP2 and human PARP15, respectively .

HY-14478

UPF 1069 1 Publications Verification	PARP	Cancer
UPF 1069 is a *PARP* inhibitor, with IC₅₀s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively.

HY-151625

PARP-2-IN-3	PARP Apoptosis	Cancer
PARP-2-IN-3 (Compound 12) is a potent *PARP-2* inhibitor with an IC₅₀ of 0.07 μM. PARP-2-IN-3 induces apoptosis and necrosis in cancer cells. PARP-2-IN-3 shows appropriate predicted pharmacokinetic parameters and oral bioavailability .

HY-164757

PARP-1-IN-32	Poly(ADP-ribose) Glycohydrolase (PARG)	Cancer
PARP-1-IN-32 (compound 15) is a poly (ADPribose) polymerase-1 (PARP-1) inhibitor. PARP-1-IN-32 can be used in cancer research .

HY-148566

OUL232	PARP	Cancer
OUL232 is a potent inhibitor of mono-ARTs PARP7, PARP10, PARP11, PARP12, PARP14, and *PARP15. OUL232 is the most potent PARP10* inhibitor described to date (IC₅₀=7.8 nM), as well as the first *PARP12* inhibitor ever reported .

HY-146336

PARP1/2/TNKS1/2-IN-1	PARP Apoptosis	Cancer
PARP1/2/TNKS1/2-IN-1 (Compound I-9) is a dual *PARP-1, PARP-2, TNKS1* and TNKS2 inhibitor with IC₅₀ values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM against PARP-1, PARP-2, TNKS1 and TNKS2, respectively. PARP1/2/TNKS1/2-IN-1 exhibits favorable synergistic antitumor efficacy and induces apoptosis .

HY-N8481

3,6-Dihydroxyflavone 1 Publications Verification 3,6-DHF	Apoptosis	Cancer
3,6-Dihydroxyflavone is an anti-cancer agent. 3,6-Dihydroxyflavone dose- and time-dependently decreases cell viability and induces apoptosis by activating caspase cascade, cleaving poly (ADP-ribose) polymerase (PARP). 3,6-Dihydroxyflavone increases intracellular oxidative stress and lipid peroxidation .

HY-102035

PARP-2-IN-1	PARP	Cancer
PARP-2-IN-1 is a potent and selective *PARP-2* inhibitor with an IC₅₀ of 11.5 nM.

HY-168657

PARP1/2-IN-4	PARP	Others
PARP1/2-IN-4 (compound 3) is a *PARP1/2* inhibitor .

HY-132297A

PARP1-IN-5 dihydrochloride 1 Publications Verification	PARP	Cancer
PARP1-IN-5 dihydrochloride is a low toxicity, orally active, potent and selective *PARP-1* inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer .

HY-132297

PARP1-IN-5	PARP	Cancer
PARP1-IN-5 is a low toxicity, orally active, potent and selective *PARP-1* inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 can be used for the research of cancer .

HY-163658

PARP-1-IN-23	PARP	Cancer
PARP-1-IN-23 (Compound I16 ) is an orally active and selective *PARP-1* inhibitor with the IC₅₀ of 12.38 nM. PARP-1-IN-23 inhibits tumor growth in vivo .

HY-147886

PARP1-IN-11	PARP	Cancer
PARP1-IN-11 (compound 49) is a potent *PARP1* inhibitor with IC₅₀ value of 0.082 µM. PARP1-IN-11 shows complete inhibition of PARP2 and substantially inhibits PARP3, TNKS1 and TNKS2 .

HY-146502

PARP10/15-IN-3	PARP Apoptosis	Cancer
PARP10/15-IN-3 (Compound 8a) is a potent *PARP10* and *PARP15* dual inhibitor with IC₅₀ values of 0.14 µM and 0.40 µM against PARP10 and PARP15, respectively. PARP10/15-IN-3 is able to enter cells and rescue cells from apoptosis .

HY-151624

PARP-2-IN-2	PARP Apoptosis	Cancer
PARP-2-IN-2 (compound 27) is a *PARP‑2* inhibitor with an IC₅₀ value of 0.057 µM. PARP-2-IN-2 induces cell cycle arrest and apoptosis of MCF-7 breast cancer cells. PARP-2-IN-2 can be used for the research of cancer .

HY-168094

PARP1-IN-30	PARP	Cancer
PARP1-IN-30 (Compound 3) is a specific and potent *PARP1* inhibitor with cytotoxicity. PARP1-IN-30 allows precise inhibition of *PARP1* in tumor cells with breast cancer 1 protein (BRCA1) or BRCA2 deficiencies. PARP1-IN-30 is promising for research of cancers .

HY-156419A

PARP7-IN-16 free base	PARP	Cancer
PARP7-IN-16 free base is the free base form of PARP7-IN-16 (HY-156419). PARP7-IN-16 free base is a selective and orally active inhibitor of *PARP-1/2/7, with IC₅₀s of 0.94, 0.87 and 0.21 nM, respectively. PARP*7-IN-16 can be used for the research of breast cancer and prostate cancer .

HY-155246

PARP1-IN-15	Apoptosis PARP	Cancer
PARP1-IN-15 (Compound 6) is a *PARP1* inhibitor. PARP1-IN-15 inhibits tankyrase (TNKS) and facilitates DNA double-strand breaks damage. PARP1-IN-15 induces tumor cell apoptosis. PARP1-IN-15 has anti-cancer activity in triple-negative breast cancer (TNBC) cells and TNBC patient-derived organoids. PARP1-IN-15 can be used for research of TNBC with or without BRCA1 mutations .

HY-119653

AZ9482	PARP	Cancer
AZ9482 is a triple *PARP1/2/6* inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively .

Cat. No.	Product Name

HY-L173

Anti-Ovarian Cancer Compound Library

2,133 compounds

Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.

MCE designs a unique collection of 2,133 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

HY-L188

Anti-Brain Cancer Compound Library

1,603 compounds

Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets.

MCE designs a unique collection of 1,603 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.

Cat. No.	Product Name	Target	Research Area

HY-P3993A

(Gly14)-Humanin (human) (acetate) 14-Glycine-Humanin (human) (acetate)	Apoptosis	Neurological Disease
(Gly14)-Humanin (human) (14-Glycine-Humanin (human)) acetate is an analog of Humanin in which the 14th amino acid serine was replaced with glycine (Gly). (Gly14)-Humanin (human) acetate has anti-apoptotic and neuroprotective functions .

HY-P2569

Malformin A1	Apoptosis	Cancer
Malformin A1, a cyclic pentapeptide isolated from Aspergillus niger, possess a range of bioactive properties including antibacterial activity. Malformin A1 shows potent cytotoxic activities on human colorectal cancer cells. Malformin A1 induces apoptosis by activating PARP, caspase 3, -7, and -9 .

HY-P3993

(Gly14)-Humanin (human) 14-Glycine-Humanin (human)	Apoptosis	Neurological Disease
(Gly14)-Humanin (human) (14-Glycine-Humanin (human)) is an analog of Humanin in which the 14th amino acid serine was replaced with glycine (Gly). (Gly14)-Humanin (human) has anti-apoptotic and neuroprotective functions .

HY-P10285

d-KLA Peptide D-(KLAKLAK)2	Mitochondrial Metabolism PARP Caspase	Cancer
d-KLA Peptide is a synthetic pro-apoptotic peptide. d-KLA Peptide can specifically target mitochondria and induce apoptosis by destroying the mitochondrial membrane. d-KLA Peptide activates biochemical pathways associated with apoptosis, including the activation of caspase family proteins and *PARP* (poly ADP ribose polymerase). d-KLA Peptide can be used to carry and deliver genes or small molecules to enhance anti-tumor effects .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6818

5,7,4'-Trimethoxyflavone MTF	Structural Classification Flavonoids Classification of Application Fields Flavones Source classification Kaempferia parviflora Wall. ex Baker Plants Disease Research Fields Zingiberaceae Cancer	Apoptosis Caspase PARP Endogenous Metabolite CFTR
5,7,4’-Trimethoxyflavone can be isolated from the medicinal plant Kaempferia parviflora (KP). 5,7,4’-Trimethoxyflavone is a CFTR activator and EC₅₀ is 64 μM. 5,7,4’-Trimethoxyflavone induces apoptosis, increases proteolytic activation of caspase-3, and degradation of ADP-ribose polymerase *(PARP)* protein. 5,7,4’-Trimethoxyflavone has antitumor activity. 5,7,4’-Trimethoxyflavone can be used to prevent skin aging and oxidative stress .

HY-113432

Nudifloramide 2PY	Alkaloids Structural Classification Other disease Classification of Application Fields Source classification Disease markers Pyridine Alkaloids Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite PARP
Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .

HY-113432R

Nudifloramide (Standard) 2PY (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Endogenous Metabolite PARP
Nudifloramide (Standard) is the analytical standard of Nudifloramide. This product is intended for research and analytical applications. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .

HY-N1988

Cucurbitacin IIa Hemslecin A	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Cucurbitaceae Plants Hemsleya chinensis Cogn. ex Forbes et Hemsl. Disease Research Fields Cancer	Survivin Apoptosis
Cucurbitacin IIa is a triterpene isolated from Hemsleya amalils Diels, induces apoptosis of cancer cells, reduces expression of survivin, reduces phospho-Histone H3 and increases cleaved PARP in cancer cells .

HY-N7569

Demethoxyfumitremorgin C	Structural Classification Alkaloids Microorganisms Source classification Marine natural products Other marine organisms Indole Alkaloids	Apoptosis Caspase PPAR
Demethoxyfumitremorgin C is a secondary metabolite of the marine fungus, Aspergillus fumigatus. Demethoxyfumitremorgin C induces prostate cancer cell apoptosis. Demethoxyfumitremorgin C activates caspase-3, -8, and -9, leading to **PARP/ cleavage .**

HY-P2569

Malformin A1	Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Apoptosis
Malformin A1, a cyclic pentapeptide isolated from Aspergillus niger, possess a range of bioactive properties including antibacterial activity. Malformin A1 shows potent cytotoxic activities on human colorectal cancer cells. Malformin A1 induces apoptosis by activating PARP, caspase 3, -7, and -9 .

HY-N10481

Aviculin	Classification of Application Fields Polygonum aviculare L. Polygonaceae Source classification Lignans Phenylpropanoids Plants Disease Research Fields Cancer	Apoptosis Caspase PARP Bcl-2 Family
Aviculin, a lignan glycoside, is a potent anticancer agent. Aviculin reduces metabolic activity on MCF-7 cells below 50%, with an IC₅₀ of 75.47 μM. Aviculin induces breast cancer cell apoptosis through the intrinsic apoptosis pathway. Aviculin increases expression of initiator caspase-9, executioner caspase-7, and poly (ADP-ribose) polymerase (PARP). Aviculin shows an increase in the Bax/Bcl-2 ratio .

HY-N6818R

5,7,4'-Trimethoxyflavone (Standard) MTF (Standard)	Structural Classification Flavonoids Flavones Source classification Kaempferia parviflora Wall. ex Baker Plants Zingiberaceae	Apoptosis Caspase PARP Endogenous Metabolite CFTR
5,?7,?4'-Trimethoxyflavone (Standard) is the analytical standard of 5,?7,?4'-Trimethoxyflavone. This product is intended for research and analytical applications. 5,7,4’-Trimethoxyflavone can be isolated from the medicinal plant Kaempferia parviflora (KP). 5,7,4’-Trimethoxyflavone is a CFTR activator and EC₅₀ is 64 μM. 5,7,4’-Trimethoxyflavone induces apoptosis, increases proteolytic activation of caspase-3, and degradation of ADP-ribose polymerase (PARP) protein. 5,7,4’-Trimethoxyflavone has antitumor activity. 5,7,4’-Trimethoxyflavone can be used to prevent skin aging and oxidative stress .

HY-W748509

Pipernonaline	Piper longum Linn. Structural Classification Alkaloids Piperidine Alkaloids Source classification Piperaceae Plants	Caspase Apoptosis
Pipernonaline is a piperine derivative with antiprostate cancer activity. Pipernonaline inhibits the proliferation of androgen-dependent/independent LNCaP/PC-3 prostate cells. Pipernonaline activates caspase-3 and promotes procaspase-3/PARP cleavage. Pipernonaline also mediates reactive oxygen species (ROS) production, increased intracellular Ca(2+), and mitochondrial membrane depolarization .

HY-130476

Satratoxin G	Structural Classification Microorganisms Terpenoids Sesquiterpenes Source classification	Caspase Apoptosis
Satratoxin G is a large cyclic mucor toxin. Satratoxin G induces apoptosis by activation of caspase .

HY-122935

Nigranoic acid	Infection Triterpenes Classification of Application Fields Terpenoids Source classification Plants Schisandraceae Disease Research Fields Schisandra chinensis (Turcz.) Baill.	HIV Reverse Transcriptase
Nigranoic acid is a triterpenoid separated from Schisandra chinensis. Nigranoic acid inhibits HIV-1 reverse transcriptase. Nigranoic acid exhibits protective effects on brain through PARP/AIF signaling pathway in cerebral ischemia-reperfusion animal model .

HY-N6861

Lucidenic acid B	Triterpenes Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Terpenoids Source classification Polyporaceae Plants Endogenous metabolite Disease Research Fields Cancer	Apoptosis
Lucidenic acid B is a natural compound isolated from Ganoderma lucidum, induces apoptosis of cancer cells, and causes the activation of caspase-9 and caspase-3, and cleavage of PARP. Lucidenic acid B does not affect the cell cycle profile, or the number of necrotic cells .

HY-N3584

Paris saponin VII 2 Publications Verification Chonglou Saponin VII	Structural Classification Liliaceae Classification of Application Fields Source classification Trillium tschonoskii Maxim. Plants Disease Research Fields Steroids Cancer	Akt p38 MAPK P-glycoprotein Bcl-2 Family Caspase PARP Autophagy Apoptosis
Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of *Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt*. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia .

HY-130073

Amorfrutin A	Structural Classification Simple Phenylpropanols Leguminosae Source classification Amorpha fruticosaL. Phenylpropanoids Plants	NF-κB Apoptosis
Amorfrutin A is the inhibition of NF-κB activation, that inhibits TNF-α-induced IκBα degradation, p65 nuclear translocation, and DNA-binding activity. Amorfrutin A promotes TNF-α-induced apoptosis in HeLa cell through promotion of caspase-3 and PARP proteolysis .

HY-N1988R

Cucurbitacin IIa (Standard)	Triterpenes Structural Classification Terpenoids Source classification Cucurbitaceae Plants Hemsleya chinensis Cogn. ex Forbes et Hemsl.	Survivin Apoptosis
Cucurbitacin IIa (Standard) is the analytical standard of Cucurbitacin IIa. This product is intended for research and analytical applications. Cucurbitacin IIa is a triterpene isolated from Hemsleya amalils Diels, induces apoptosis of cancer cells, reduces expression of survivin, reduces phospho-Histone H3 and increases cleaved PARP in cancer cells .

HY-N3825

ent-Kaurane-3α,16β,17-triol	Structural Classification Terpenoids Source classification Euphorbia stracheyi Boiss. Diterpenoids Euphorbiaceae Plants	Apoptosis
ent-Kaurane-3α,16β,17-triol (Compound 3) is an anticancer agent. ent-Kaurane-3α,16β,17-triol induces apoptosis in HCT116 cells .

HY-N3584R

Paris saponin VII (Standard)	Structural Classification Liliaceae Source classification Trillium tschonoskii Maxim. Plants Steroids	Akt p38 MAPK P-glycoprotein Bcl-2 Family Caspase PARP Autophagy Apoptosis
Paris saponin VII (Standard) is the analytical standard of Paris saponin VII. This product is intended for research and analytical applications. Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia .

HY-Z0283

Benzamide Benzenecarboxamide; Phenylamide	Structural Classification Alkaloids Human Gut Microbiota Metabolites Classification of Application Fields Other Alkaloids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite PARP
Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-N0674A

Dehydrocorydaline chloride Maximum Cited Publications 28 Publications Verification 13-Methylpalmatine chloride	Infection Alkaloids Structural Classification other families Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Disease Research Fields	Bcl-2 Family Caspase PARP p38 MAPK Parasite Autophagy
Dehydrocorydaline chloride (13-Methylpalmatine chloride) is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates *PARP* . Dehydrocorydaline chloride elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities . Dehydrocorydaline chloride shows strong anti-malarial effects (IC₅₀ =38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain .

HY-N1970

5,7-Dihydroxychromone 1 Publications Verification	Structural Classification Flavonoids other families Source classification Phenols Polyphenols Plants Isoflavones	Keap1-Nrf2 Arenavirus Caspase PARP
5,7-Dihydroxychromone, the extract of Cudrania tricuspidata, activates Nrf2/ARE signal and exerts neuroprotective effects against 6-hydroxydopamine (6-OHDA)-induced oxidative stress and apoptosis. 5,7-Dihydroxychromone inhibits the expression of activated caspase-3 and caspase-9 and cleaved *PARP* in 6-OHDA-induced SH-SY5Y cells .

HY-Z0283R

Benzamide (Standard)	Structural Classification Alkaloids Human Gut Microbiota Metabolites Other Alkaloids Source classification Endogenous metabolite	Endogenous Metabolite PARP
Benzamide (Standard) is the analytical standard of Benzamide. This product is intended for research and analytical applications. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-N0674

Dehydrocorydaline Maximum Cited Publications 28 Publications Verification 13-Methylpalmatine	Infection Alkaloids Structural Classification Corydalis yanhusuo W. T. Wang Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Disease Research Fields Papaveraceae	Bcl-2 Family Caspase PARP p38 MAPK Parasite Autophagy
Dehydrocorydaline (13-Methylpalmatine) is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates *PARP* . Dehydrocorydaline elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities . Dehydrocorydaline shows strong anti-malarial effects (IC₅₀=38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain .

HY-N0674B

Dehydrocorydaline (hydroxyl) Maximum Cited Publications 28 Publications Verification 13-Methylpalmatine (hydroxyl)	Structural Classification Alkaloids Corydalis yanhusuo W. T. Wang Source classification Plants Papaveraceae	Bcl-2 Family Caspase PARP p38 MAPK Parasite Autophagy
Dehydrocorydaline (13-Methylpalmatine) hydroxyl is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP. Dehydrocorydaline hydroxyl elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities. Dehydrocorydaline hydroxyl shows strong anti-malarial effects (IC50=38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain.

HY-N4238

Dehydrocorydaline nitrate Maximum Cited Publications 28 Publications Verification 13-Methylpalmatine nitrate	Infection Alkaloids other families Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Disease Research Fields	Bcl-2 Family Caspase PARP p38 MAPK Parasite Autophagy
Dehydrocorydaline nitrate (13-Methylpalmatine nitrate) is an alkaloid. Dehydrocorydaline regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates *PARP* . Dehydrocorydaline nitrate elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities. . Dehydrocorydaline nitrate shows strong anti-malarial effects (IC₅₀ =38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain .

HY-N6969A

Dicentrine hydrochloride	Structural Classification Alkaloids Other Alkaloids Source classification Stephania epigaea Lo Plants Menispermaceae	Adrenergic Receptor
Dicentrine hydrochloride is a drug with anti-inflammatory and anti-cancer activity. Dicentrine hydrochloride exerts its effects by enhancing TNF-α-induced apoptosis in A549 lung adenocarcinoma cells. Dicentrine hydrochloride increases caspase-8, -9, -3 and poly(ADP-ribose) polymerase (PARP) activities. Dicentrine hydrochloride inhibits TNF-α-induced invasion and migration of A549 cells. Dicentrine hydrochloride significantly inhibited the TNF-α-activated TAK1, p38, JNK and Akt signaling pathways, and reduced the transcriptional activities of NF-κB and AP-1 .

HY-N1970R

5,7-Dihydroxychromone (Standard)	Structural Classification Flavonoids other families Source classification Phenols Polyphenols Plants Isoflavones	Keap1-Nrf2 Arenavirus Caspase PARP
5,7-Dihydroxychromone (Standard) is the analytical standard of 5,7-Dihydroxychromone. This product is intended for research and analytical applications. 5,7-Dihydroxychromone, the extract of Cudrania tricuspidata, activates Nrf2/ARE signal and exerts neuroprotective effects against 6-hydroxydopamine (6-OHDA)-induced oxidative stress and apoptosis. 5,7-Dihydroxychromone inhibits the expression of activated caspase-3 and caspase-9 and cleaved PARP in 6-OHDA-induced SH-SY5Y cells .

HY-127057

Lambertianic acid	Pinus lambertiana Douglas Structural Classification Pinaceae Terpenoids Source classification Diterpenoids Plants	Androgen Receptor CDK MDM-2/p53 Apoptosis Caspase PARP Bcl-2 Family
Lambertianic acid is a bioactive diterpene with anti-allergic, antibacterial and anticancer activities. Lambertianic acid decreases androgen receptor protein levels, cellular and secretory levels of prostate-specific antigen. Lambertianic acid also suppresses cell proliferation by inducing G1 arrest, downregulating CDK4/6 and cyclin D1, activating p53, p21 and p27. Lambertianic acid induces Apoptosis and the expression of related proteins, including cleaved caspase-3/9, c-PARP and BAX, and inhibited BCl-2. Lambertianic acid is promising for research of prostate cancer .

HY-123033A

Nicotinamide riboside chloride 10+ Cited Publications	Alkaloids Structural Classification Animals Neurological Disease Classification of Application Fields Anti-aging Source classification Pyridine Alkaloids Metabolic Disease Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside Chloride, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside Chloride is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside Chloride reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-123033

Nicotinamide riboside	Natural Products Human Gut Microbiota Metabolites Microorganisms Animals Neurological Disease Classification of Application Fields Anti-aging Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-123033B

Nicotinamide riboside tartrate	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside tartrate, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside tartrate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside tartrate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-123033C

Nicotinamide riboside malate	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside malate, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside malate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside malate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-N8572

3',4'-Dimethoxyflavone	Structural Classification Flavonoids other families Flavones Coniogramme japonica (Thunb.) Diels Plants	PARP Reactive Oxygen Species Aryl Hydrocarbon Receptor
3',4'-Dimethoxyflavone is a lipophilic flavone, can be isolated from the leaves of Primula veris. 3',4'-Dimethoxyflavone can reduce the synthesis and accumulation of *PARP* and protect cortical neurones against cell death induced by Parthanatos. 3',4'-Dimethoxyflavone is also an aryl hydrocarbon receptor antagonist in human breast cancer cells. 3',4'-Dimethoxyflavone can promote the proliferation of human hematopoietic stem cells. 3',4'-Dimethoxyflavone has various biological activities, including antioxidant, anti-cancer, anti-inflammatory, anti-atherogenic, hypolipidaemic, and neuroprotective or neurotrophic effects .

Cat. No.	Product Name	Chemical Structure

HY-10162S

Olaparib-d5
Olaparib-d₅ is a deuterium labeled Olaparib. Olaparib is a potent and oral PARP inhibitor[1].

HY-Z0283S

Benzamide-15N
Benzamide- ¹⁵N is a ¹⁵N-labeled Benzamide. Benzamide inhibits poly(ADP-ribose) polymerase (PARP)[1][2].

HY-10162S1

Olaparib-d8
Olaparib-d₈ is the deuterium labeled Olaparib (AZD2281). Olaparib is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].

HY-10162S3

Olaparib-d4-1
Olaparib-d₄-1 is the deuterium labeled Olaparib. Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].

HY-16106S

Talazoparib-13C,d4
Talazoparib- ¹³C,d4 is ¹³C and deuterated labeled Talazoparib (HY-16106). Talazoparib is an orally active PARP 1/2 inhibitor with Ki values of 1.2 nM and 0.87 nM for inhibiting PARP1 and PARP2 enzymatic activities, respectively. Has anti-tumor activity.

HY-113432S

Nudifloramide-d3
Nudifloramide-d₃ (2PY-d3) is the deuterium labeled Nudifloramide. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro[1].

Cat. No.	Product Name		Classification

HY-150221

DB008		Alkynes
DB008 is potent and selective *PARP16* inhibitor with an IC₅₀ value of 0.27 μM, containing an acrylamide electrophilic reagent. DB008 is membrane-permeable and marks PARP16 selectively . DB008 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-130652

Pomalidomide 4'-PEG3-azide		Azide
Pomalidomide 4'-PEG3-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide-based cereblon ligand and a linker. Pomalidomide 4'-PEG3-azide can be used for the synthesis of iRucaparib-TP3 (Compound 3). iRucaparib-TP3 is a highly efficient *PARP1*?degrader based on Rucaparib by using the PROTAC approach . Pomalidomide 4'-PEG3-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-W021401

Amino-PEG3-C2-Azido		PROTAC Synthesis Azide
Amino-PEG3-C2-Azido is a PEG-based PROTAC linker can be used in the synthesis of the PARP1 degrader iRucaparib-TP3 (HY-130645) . Amino-PEG3-C2-Azido is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-145749

PARPYnD		Alkynes
PARPYnD is a *PARP* enzyme photoaffinity probe (AfBP) based on the triple *PARP1/2/6* inhibitor AZ9482 (HY-119653), which induces breast cancer Formation of multipolar spindles (MPS) in cells. PARPYnD inhibits PAPR wih IC₅₀ of 38 nM (PARP1), 6 nM (PARP2), 230 nM (PARP6), respectively. PARPYnD enriches recombinant PARP6 incorporated into cell lysates and inhibits PARP6 in cell-free assays, but it does not label PARP6 in intact cells .

HY-130654

(S,R,S)-AHPC-C2-PEG4-N3 VH032-C2-PEG4-N3		Azide
(S,R,S)-AHPC-C2-PEG4-N3 (VH032-C2-PEG4-N3) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology. (S,R,S)-AHPC-C2-PEG4-N3 can be used in the synthesis of vRucaparib-TP4 (HY-130647). vRucaparib-TP4 a highly potent PARP1 degrader with a half-maximal degrading concentration (DC₅₀) of 82 nM . (S,R,S)-AHPC-C2-PEG4-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Cat. No.	Product Name		Classification

HY-RS10047

PARP1 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP1 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10048

Parp1 Mouse Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Parp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10049

Parp1 Rat Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Parp1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10050

PARP10 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP10 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10051

Parp10 Mouse Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp10 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Parp10 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10052

Parp10 Rat Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp10 Rat Pre-designed siRNA Set A contains three designed siRNAs for Parp10 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10053

PARP11 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP11 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10054

PARP12 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP12 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP12 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10055

PARP14 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP14 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10056

Parp14 Mouse Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp14 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Parp14 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10057

Parp14 Rat Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp14 Rat Pre-designed siRNA Set A contains three designed siRNAs for Parp14 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10058

PARP15 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP15 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP15 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10059

PARP16 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP16 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP16 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10060

PARP2 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP2 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10061

Parp2 Mouse Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Parp2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10062

Parp2 Rat Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Parp2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10063

PARP3 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP3 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10064

Parp3 Mouse Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Parp3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10065

Parp3 Rat Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Parp3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10066

PARP4 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP4 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10067

Parp4 Mouse Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Parp4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10068

Parp4 Rat Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Parp4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10069

PARP6 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP6 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10070

PARP8 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP8 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10071

PARP9 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP9 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-152696

6-O-Methylinosine		Nucleosides and their Analogs
6-O-Methylinosine is a hypoxanthine analogue. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-154017

2′-C-Methyl-6-O-methylinosine		Nucleosides and their Analogs
2′-C-Methyl-6-O-methylinosine is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-154393

2-Chloro-2'-deoxy-6-O-methylinosine		Nucleosides and their Analogs
2-Chloro-2'-deoxy-6-O-methylinosine is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-152678

6-Methoxypurine-9-β-D-5’(R)-C-methylriboside		Nucleosides and their Analogs
6-Methoxypurine-9-β-D-5’(R)-C-methylriboside is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-W141392

2'-Fluoro-5'-O-DMT-2'-deoxyinosine-3'-CE-phosphoramidite		Nucleoside Phosphoramidites
2'-Fluoro-5'-O-DMT-2'-deoxyinosine-3'-CE-phosphoramidite is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-W392836

2'-O-Methyl-5'-O-dmt-inosine-3'-CE-phosphoramidite		Nucleoside Phosphoramidites
2'-O-Methyl-5'-O-dmt-inosine-3'-CE-phosphoramidite is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PARPs

Inhibitors & Agonists

Screening Libraries

Peptides

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products